AZD2014 + Fulvestrant for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Will I have to stop taking my current medications?
The trial requires that you stop taking any chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, and any investigational agents at least 14 days before starting the study treatment.
Is the combination of AZD2014 and Fulvestrant safe for humans?
Fulvestrant (Faslodex) has been used in many patients with advanced breast cancer and is generally well tolerated, with only a small percentage experiencing side effects. While specific safety data for AZD2014 in combination with Fulvestrant is not provided, Fulvestrant alone has shown a good safety profile in clinical settings.12345
How does the drug AZD2014 + Fulvestrant differ from other breast cancer treatments?
What data supports the effectiveness of the drug AZD2014 + Fulvestrant for breast cancer?
Fulvestrant (Faslodex) has shown effectiveness in treating advanced breast cancer, especially in postmenopausal women who have not responded to other endocrine therapies. It is at least as effective as anastrozole, another breast cancer treatment, providing a valuable option for patients with advanced disease.5691011
Who Is on the Research Team?
Howard Burris, MD
Principal Investigator
SCRI Development Innovations, LLC
Are You a Good Fit for This Trial?
This trial is for adults over 18 with ER+ advanced metastatic breast cancer, who can provide consent and have at least one lesion visible on scans. They must be in good physical condition (ECOG 0 or 1) and not able to bear children. Excluded are those who've had recent cancer treatments, severe heart conditions, major surgery within the last month, minor surgery within two weeks, or uncontrolled type I or II diabetes.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AZD2014 orally in combination with intramuscular Fulvestrant
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AZD2014
- Fulvestrant
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology